TScan Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
TCRX$0.19+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(106,789) | $(91,690) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 2,143 | 3,397 |
| Accretion of marketable securities | (2,354) | (2,347) |
| Non-cash interest expense related to note payable | 342 | 600 |
| Stock-based compensation | 9,698 | 6,835 |
| Changes in current assets and liabilities: | ||
| Prepaid expenses and other assets | 378 | (932) |
| Right-of-use assets and lease liabilities, net | 2,818 | 995 |
| Accounts payable | 2,056 | 1,011 |
| Accrued expense and other liabilities | (3,851) | 870 |
| Deferred revenue | (7,758) | (2,149) |
| Net cash used in operating activities | (103,317) | (83,410) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (4,236) | (2,937) |
| Purchases of marketable securities | (87,471) | (194,116) |
| Maturities of marketable securities | 186,250 | 117,147 |
| Net cash provided by (used in) investing activities | 94,543 | (79,906) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of offering costs | - | 33,131 |
| Proceeds from issuance of pre-funded warrants, net of offering costs | - | 128,272 |
| Proceeds from exercise of stock options | - | 1,672 |
| Proceeds from issuance of common stock under employee stock purchase plan | 191 | - |
| Cash paid for debt issuance costs | (400) | - |
| Cash paid for financing costs | (200) | - |
| Net cash provided by (used in) financing activities | (409) | 163,075 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (9,183) | (241) |
| Cash, cash equivalents, and restricted cash - beginning of period | 183,720 | 138,390 |
| Cash, cash equivalents, and restricted cash - end of period | $174,537 | $138,149 |
| Summary of cash, cash equivalents and restricted cash reported within the consolidated balance sheets: | ||
| Cash and cash equivalents | 169,506 | 133,118 |
| Restricted cash | 5,031 | 5,031 |
| Total cash, cash equivalents, and restricted cash | $174,537 | $138,149 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $1,725 | $2,269 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Purchase of property and equipment in accounts payable and accrued liabilities | $52 | $480 |
TSCAN THERAPEUTICS, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.